Sam Craft

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Topics

Cross Sectional

Patient Reported

Health Insurance

Top Venues

Addiction (Abingdon, England)

Psychological medicine

Psychopharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Sam Craft, Peter Sunderland, Molly F Millea, Christopher R Pudney, Oliver B Sutcliffe, Tom P Freeman
Detection and quantification of synthetic cannabinoids in seven illicitly sourced disposable vapes submitted by an individual presenting to a UK drug and alcohol service. Addiction (Abingdon, England) (2024)
Martine Skumlien, Sam Craft
Commentary on Allaf et al.: Comparing countries with different legal cannabis markets can inform on the impact of regulating product type and potency. Addiction (Abingdon, England) (2023)
Sam Craft, Michael Dunn, Dan Vidler, Jane Officer, Ian S Blagbrough, Christopher R Pudney, Graeme Henderson, Ahmed Abouzeid, Paul I Dargan, Michael Eddleston, Jamie Cooper, Simon L Hill, Clair Roper, Tom P Freeman, Simon H L Thomas
Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act. Addiction (Abingdon, England) 117 (11) (2022)
Sam Craft, Jason A Ferris, Monica J Barratt, Larissa J Maier, Michael T Lynskey, Adam R Winstock, Tom P Freeman
Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis. Psychopharmacology (2021)
Tom P Freeman, Sam Craft, Jack Wilson, Stephan Stylianou, Mahmoud ElSohly, Marta Di Forti, Michael T Nurmohamed
Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction (Abingdon, England) 116 (5) (2020)
Sam Craft, Adam Winstock, Jason Ferris, Clare Mackie, Michael T Lynskey, Tom P Freeman
Characterising heterogeneity in the use of different cannabis products: latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence. Psychological medicine 50 (14) (2019)